Quantinno Capital Management LP Sells 3,803 Shares of Zai Lab Limited (NASDAQ:ZLAB)

Quantinno Capital Management LP trimmed its holdings in Zai Lab Limited (NASDAQ:ZLAB) by 28.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,631 shares of the company’s stock after selling 3,803 shares during the quarter. Quantinno Capital Management LP’s holdings in Zai Lab were worth $232,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its stake in Zai Lab by 34.2% in the third quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company’s stock valued at $211,488,000 after buying an additional 2,232,507 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Zai Lab by 26.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company’s stock valued at $14,584,000 after acquiring an additional 125,532 shares in the last quarter. Bamco Inc. NY lifted its position in shares of Zai Lab by 6.4% during the 3rd quarter. Bamco Inc. NY now owns 1,906,520 shares of the company’s stock valued at $46,023,000 after acquiring an additional 113,869 shares during the period. Algert Global LLC bought a new position in Zai Lab during the third quarter worth $1,666,000. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in Zai Lab by 96.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 124,096 shares of the company’s stock worth $2,151,000 after purchasing an additional 60,927 shares during the period. Institutional investors and hedge funds own 41.65% of the company’s stock.

Zai Lab Price Performance

Shares of NASDAQ ZLAB opened at $26.18 on Tuesday. Zai Lab Limited has a 1 year low of $13.48 and a 1 year high of $36.60. The stock has a market capitalization of $2.84 billion, a P/E ratio of -9.45 and a beta of 0.99. The company has a 50-day moving average price of $28.22 and a 200-day moving average price of $22.34.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on ZLAB shares. JPMorgan Chase & Co. increased their price objective on shares of Zai Lab from $38.00 to $44.00 and gave the stock an “overweight” rating in a research report on Monday, October 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research note on Friday, October 25th.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.